MRINZ Researchers Appointed to Te Niwha–Infectious Disease Research Platform Advisory Group
Two senior MRINZ researchers, Dr Max Bloomfield and Dr Tom Hills, have been appointed to the Te Niwha–Infectious Disease Research Platform Advisory Group, supporting the development of New Zealand’s next phase of infectious disease research.
The Platform aims to strengthen New Zealand’s economic and social resilience to infectious disease threats through world-class science and coordinated capability. To guide its development, a Transitional Infectious Diseases Research Advisory Group has been established, chaired by Professor David Murdoch and including experts from across the research, health, and policy sectors.
The Advisory Group’s work involves framing priority areas for the Platform, taking into account the interdisciplinary nature of infectious diseases, perspectives from researchers, policy partners, and Māori and Pacific communities, as well as alignment with New Zealand’s current and emerging needs. The group will also focus on sustaining momentum and continuity from the initial funding tranche.
The Advisory Group includes a broad mix of expertise: Associate Professor Emma Best, Dr Rose Collis, Dr Mae David, Dr Nick Douglas, Professor Jemma Geoghegan, Professor David Hayman, Dr Sarah Jefferies, Dr Mike Maze, Dr Natalie Netzler, Professor Colin Simpson, Glenda Raumati, Dr Max Bloomfield and Dr Tom Hills, with operational support provided by Maree Roberts, Interim Director of Te Niwha.
A recent Advisory Group meeting was held at Auckland University, bringing together members to advance planning for the Platform and ensure alignment with the needs of the research community, policy partners, and New Zealanders more broadly.
Once a draft Research Plan has been developed, the Platform will engage widely with stakeholders to gather input and feedback, ensuring that the final plan reflects the perspectives of researchers, communities, and policymakers.
The Te Niwha–Infectious Disease Research Platform marks a significant advance in New Zealand’s coordinated approach to infectious disease research, with MRINZ contributing its expertise to strengthen the country’s capability and readiness.
